The first clinical trial involving human subjects in Phase I demonstrated that the utilization of nanoparticle p53 led to the restoration of p53 protein levels while achieving high drug accumulation at the tumor site and maintaining a relatively favorable safety profile [221]. Here, TP53 is linked to neoplasm.